We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > pneumococcal disease

News List

Serum Institute of India launches indigenously developed pneumococcal vaccine, ‘PNEUMOSIL’ expresspharma
December 29, 2020
This WHO pre-qualified PCV is specially tailored to the prevailing serotype prevalence of S. pneumoniae in India and other regions of the world.
Pfizer’s pneumococcal disease vaccine scores FDA priority review pharmatimes
December 10, 2020
The US Food and Drug Administration (FDA) has granted Pfizer’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate a priority review for the prevention of pneumococcal disease.
Pfizer’s 13-valent PCV selected in India’s immunisation programme pharmaceutical-technology
May 16, 2017
Pharmaceutical firm Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) has been selected in India’s immunisation programme in selected states.
India to immunise five million using Pfizer pneumococcal disease vaccine pharmafile
May 15, 2017
An Indian immunisation programme will make use of Pfizer’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) to treat around 5.15 million, or 20%, of the country’s at-risk infants in an attempt to neutralise the effects of one of India’s biggest killers o